TP53 and colorectal carcinoma: Additionally, multiple studies have demonstrated that inhibition of GSK-3 activity may still have therapeutic potential in the management of CRC through the induction of P53 dependent and independent apoptosis [184,185,186,187,188,189], downregulating EMT [190,191,192,193], re-establishing Hedgehog signaling [194], and disrupting malignant cytoskeletal dependencies [190,195,196].